Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is positioned to disrupt the current standard of care for sleep-disordered breathing with their non-surgical, non-invasive, and low-cost solution. With over 30 million adults in the U.S. affected by this condition and low long-term compliance rates for the current standard of care, Vivos' proprietary technology and protocols offer a promising alternative. While the company may require additional financing in the near term, recent fundings and new partnerships demonstrate strong support for Vivos' growth potential. However, investors should be aware of risks such as changing macroeconomic factors and competition in the market.

Vivos Therapeutics is facing challenges in its business model transition, as seen in their negative earnings per share and decrease in revenue projections for 2026 by over $10 million. While their gross margins have shown some improvement in Q4, uncertainties in the ramp up of revenue and higher operating expenses remain. It may be necessary for the company to undergo share dilution to raise capital, and their recent provider attrition may also impact future growth. It's important to monitor operational efficiency and revenue growth in the coming year.